Monday 19 October 2026
Export MOTS’s income statement to Excel — free account
Motus GI Holdings, Inc.
MOTS Healthcare Medical Devices
Motus GI Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $319,000.00, down 46.1% from fiscal 2022. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow MOTS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 3 | 4 | 5 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 0.94 | (2.88) | (6.64) | (7.09) | (13.69) | (34.74) |
P/S ratio |
— | 0.00 | 0.00 | 538.04 | 310.81 | 56.04 | 4.87 | 3.30 |
Altman Z″-Score (non-manufacturers) |
— | (17.31) | (4.26) | (8.21) | (15.31) | (14.15) | (28.77) | (77.80) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (16.31) | (10.71) | (10.43) | (10.22) | (5.59) | (0.71) | (0.57) |
P/B ratio |
— | 8.21 | 2.54 | 3.14 | 2.70 | 2.27 | 0.97 | 0.39 |
Price to Tangible BV |
— | 8.21 | 2.54 | 3.14 | 2.70 | 2.27 | 0.97 | 0.39 |
EV/Sales |
— | 0.00 | 0.00 | 348.66 | 185.37 | 27.45 | (0.25) | (5.12) |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.15 |
EV/Operating CF |
— | (4.15) | (2.06) | (1.87) | (1.07) | (0.74) | 0.01 | 0.15 |
EV/FCF |
— | (3.88) | (1.99) | (1.83) | (1.06) | (0.72) | 0.01 | 0.14 |
Quick Ratio |
15.48 | 3.50 | 8.82 | 2.54 | 1.97 | 6.80 | 2.94 | 1.54 |
Current Ratio |
15.94 | 4.18 | 9.21 | 2.66 | 2.08 | 7.19 | 3.20 | 1.76 |
Net Debt/EBITDA |
1.95 | 0.54 | 1.13 | 0.87 | 0.66 | 0.65 | 0.18 | 0.24 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 26.25% | 35.43% | 43.64% | 62.41% | 31.46% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.46 | 0.76 | 1.18 | 3.70 | 0.85 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.03 |
Operating CF/Net income |
0.76 | 0.79 | 0.67 | 0.86 | 0.88 | 0.57 | 0.94 | 0.87 |
Capex/Depreciation |
(0.65) | (10.88) | (2.96) | (2.06) | (0.22) | (0.59) | (0.19) | (0.11) |
Interest Coverage |
(3.06) | (2,160.67) | 183.74 | 85.85 | (41.05) | (25.00) | (14.26) | (15.65) |
| (254.46%) | (169.75%) | (185.17%) | (125.31%) | (130.04%) | (240.40%) | (294.40%) | (454.34%) | |
| (115.39%) | (123.60%) | (138.58%) | (83.63%) | (68.38%) | (100.40%) | (85.04%) | (103.47%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (744,187.50%) |
Return on Tangible Assets |
(70.52%) | (186.28%) | (108.55%) | (116.13%) | (151.93%) | (114.15%) | (156.33%) | (369.85%) |
Average Days of Receivables |
— | 0.00 | 50.69 | 283.13 | 130.36 | 101.75 | 36.38 | 86.96 |
Research and Development Expense of Revenue |
0.00% | 60,885.71% | 16,800.00% | 8,423.36% | 5,668.37% | 1,365.98% | 947.80% | 1,086.83% |
Selling, General and Administrative Expense of Revenue |
0.00% | 124,314.29% | 35,719.44% | 13,452.34% | 13,361.22% | 3,158.57% | 2,033.11% | 2,567.40% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 31,714.29% | 6,875.00% | 2,995.33% | 2,964.29% | 887.98% | 305.57% | 147.65% |
Graham Net Nets |
— | 0.10 | 0.37 | 0.28 | 0.31 | 0.34 | 0.24 | 1.16 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (29.15%) | (48.53%) | (40.59%) | (66.42%) | (117.71%) | (689.54%) | (2,196.15%) |
Free Cash Flow Yield |
— | (24.50%) | (32.85%) | (35.41%) | (56.08%) | (67.96%) | (613.50%) | (1,072.93%) |
Revenue per Share |
0.00 | 0.20 | 0.71 | 1.28 | 0.92 | 2.50 | 2.74 | 0.39 |
Operating CF per Share |
(1,612.11) | (301.39) | (295.70) | (237.65) | (158.66) | (92.21) | (80.87) | (13.82) |
Capex per Share |
(7.89) | (20.49) | (10.83) | (5.58) | (0.82) | (3.01) | (1.04) | (0.13) |
Free Cash Flow per Share |
(1,620.00) | (321.88) | (306.53) | (243.23) | (159.49) | (95.22) | (81.90) | (13.95) |
Cash per Share |
3,064.21 | 201.13 | 417.68 | 342.85 | 194.39 | 144.26 | 65.01 | 6.12 |
Shareholders Equity per Share |
2,639.21 | 160.09 | 366.67 | 218.71 | 105.42 | 61.75 | 13.78 | 3.32 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2,639.21 | 160.09 | 366.67 | 218.71 | 105.42 | 61.75 | 13.78 | 3.32 |
Free Cash Flow |
(6.16) | (11.10) | (15.48) | (20.38) | (17.08) | (14.89) | (17.69) | (11.30) |
Working Capital |
11.24 | 6.30 | 19.66 | 18.82 | 11.50 | 20.63 | 10.57 | 2.49 |
Capital Expenditures |
(0.03) | (0.71) | (0.55) | (0.47) | (0.09) | (0.47) | (0.22) | (0.10) |
Net Current Asset Value |
9.83 | 4.64 | 17.61 | 16.24 | 9.33 | 7.53 | 0.70 | 1.22 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.14 |
Capex to Sales |
0.00 | 101.00 | 15.19 | 4.37 | 0.90 | 1.20 | 0.38 | 0.33 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.33 | 0.08 | 0.22 | 0.22 | 0.34 | 0.56 | 0.88 | 0.94 |
Cash ROIC |
(28.40%) | (89.11%) | (39.08%) | (36.71%) | (42.04%) | (34.15%) | (63.11%) | (113.93%) |
Accounts Receivable Turnover |
— | 0.00 | 0.82 | 2.43 | 1.66 | 5.43 | 7.05 | 4.73 |
Accounts Payable Turnover |
0.16 | 0.07 | 0.03 | 0.05 | 0.19 | 0.25 | 0.35 | 0.30 |
Inventory Turnover |
0.19 | 1.56 | 3.72 | 0.26 | 0.55 | 0.96 | 1.62 | 1.55 |
Average Days of Payables |
849.02 | 9,302.13 | 14,464.81 | 8,048.79 | 1,716.82 | 1,511.47 | 902.87 | 1,181.60 |
Days of Inventory on Hand |
642.72 | 32.21 | 155.46 | 2,721.40 | 592.39 | 290.13 | 223.77 | 157.16 |
Average Receivables |
— | — | 0.04 | 0.04 | 0.06 | 0.07 | 0.08 | 0.07 |
Average Payables |
0.28 | 0.92 | 1.94 | 2.57 | 2.67 | 2.46 | 2.28 | 1.91 |
Average Inventory |
0.25 | 0.04 | 0.01 | 0.52 | 0.91 | 0.65 | 0.49 | 0.37 |
Average Assets |
6.95 | 10.68 | 16.06 | 27.61 | 28.16 | 25.08 | 21.87 | 12.44 |
Average Common Equity |
3.15 | 7.78 | 12.02 | 18.42 | 14.81 | 10.47 | 6.32 | 2.83 |
Columns are period end dates